<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04326166</url>
  </required_header>
  <id_info>
    <org_study_id>DA1229_DM_OS</org_study_id>
    <nct_id>NCT04326166</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.</brief_title>
  <official_title>Multi-center, Open, Non-intervention and Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab. in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, open, non-intervention and observational study to Evaluate the efficacy and
      safety of Suganon tab. or Sugamet XR tab. in patients with Type 2 diabetes
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>To assess change from baseline in HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>at 24 weeks</time_frame>
    <description>To assess change from baseline in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with HbA1c &lt;7.0% and &lt;6.5%</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>To assess the percentage of patients with HbA1c &lt;7.0% and &lt;6.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>To assess change from baseline in fasting plasma glucose (FPG)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1971</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Patients who receive Double therapy or Insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Patients who receive DPP-4 inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>Drug-naïve patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin</intervention_name>
    <description>Evogliptin</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Suganon</other_name>
    <other_name>Sugamet XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin</intervention_name>
    <description>Evogliptin</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Suganon</other_name>
    <other_name>Sugamet XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Evogliptin</intervention_name>
    <description>Metformin and Evogliptin</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>Suganon</other_name>
    <other_name>Sugamet XR</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 DM patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is aged ≥19 years

          2. The subject has type 2 diabetes mellitus

        Exclusion Criteria:

        1. The subject has a contraindication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sunhwa Lee</last_name>
    <phone>+82-2-920-8885</phone>
    <email>leesh@donga.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sanggye paik pospital</name>
      <address>
        <city>Seoul</city>
        <state>Nowon-gu</state>
        <zip>01757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong chul Won, M.D., Ph.D.</last_name>
      <phone>+82-2-950-8860</phone>
      <email>drwonjc@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

